A
Alife Health
Building tools to improve the equity and efficacy of IVF through artificial intelligence
About Alife Health
Alife Health is a technology startup that operates in the healthcare sector, specifically focusing on improving the In Vitro Fertilization (IVF) process. The company uses artificial intelligence (AI) to provide data-driven insights that help doctors make informed decisions about IVF procedures. The primary clients of Alife Health are healthcare professionals, including clinicians, embryologists, and clinic managers, who use the company's platform, Alife Assist, to optimize each step of the IVF process.
Read full description
The company's business model revolves around the development and provision of AI software that analyzes historical data to predict the most effective treatment plans for IVF patients. By doing so, Alife Health aims to improve the success rate of IVF procedures, thereby providing value to both healthcare professionals and patients. The company generates revenue by selling access to its software platform to healthcare providers.
Alife Health operates in the fertility treatment market, which is a growing sector due to increasing infertility rates and advancements in fertility treatments. The company's use of AI technology positions it well to capitalize on the trend towards data-driven decision making in healthcare.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- San Francisco, United States
- Employees
- 81
- Open positions
- None listed
- Dealroom signal
- 82.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Fertility, Biotechnology, Drug Development, Core AI, Femtech, Techbio, Hard Tech
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Alife Health.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2022 | $22M | $88M | Anarghya Vardhana · Deena Shakir · Lux Capital · Rebecca Kaden | ↗ |
| SEED✓Equity / VC | May 2021 | $9.5M | $38M | Fred Moll · Amplo · Amira Yahyaoui · Arthur Patterson | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Alife Health is 13K monthly website visits, down 51.9% over the last three months. Alife Health's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Lux Capital
Fred Moll
Amplo
Amira Yahyaoui- APArthur Patterson
Tom X. Lee
Springbank
IA Ventures
Anne Wojcicki
Series A5 investors entered at this stage
Union Square Ventures
Maveron
Anarghya Vardhana- DSDeena Shakir
- RKRebecca Kaden
Other known investors3 additional known investors
Farvatn Venture- SCSpringbank Collective
Technology Pioneers | World Economic Forum
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alife Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alife Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.